Neurological disorder

Epilepsy Foundation Expands to Middle and West Tennessee

Retrieved on: 
Wednesday, January 11, 2023
Epilepsy, Suite, 2nd Floor (Nina song), Neurological disorder, Transport, Volunteer State, EFET, Epilepsy Foundation, Head Injuries, Pharmaceutical industry, Residential care, Seizure, West Tennessee

KNOXVILLE, Tenn., Jan. 11, 2023 /PRNewswire/ -- The Epilepsy Foundation of East Tennessee (EFET) has announced the expansion of its service offerings to people with epilepsy across the entire state.

Key Points: 
  • KNOXVILLE, Tenn., Jan. 11, 2023 /PRNewswire/ -- The Epilepsy Foundation of East Tennessee (EFET) has announced the expansion of its service offerings to people with epilepsy across the entire state.
  • While the organization already had offices in East and Southeast Tennessee, it previously had no local presence in the Middle and West regions of the state.
  • State funding has allowed the Epilepsy Foundation to open and staff new local offices in Nashville, under the name Epilepsy Foundation Serving Middle Tennessee , and in Memphis, under the name Epilepsy Foundation West Tennessee .
  • "I want the Middle Tennessee office to help and support each individual with epilepsy," said Program Director Brandi Green, who runs the Nashville branch.

Theranica Enters Into Agreement With Dr. Reddy's for Commercializing Nerivio® in India

Retrieved on: 
Tuesday, January 10, 2023
Migraine, Partnership, CPM, Neurological disorder, Safety, FDA, Therapy, Laboratory, Chronic pain, REN, Quality of life, Marketing, Generic drug, Pharmaceutical industry

The Theranica and Dr. Reddy's Laboratories agreement will bring Nerivio to millions of people with migraine in India.

Key Points: 
  • The Theranica and Dr. Reddy's Laboratories agreement will bring Nerivio to millions of people with migraine in India.
  • Under the terms of the agreement, Dr. Reddy's will be responsible for the regulatory approval of Nerivio in India, after which it will exclusively market Nerivio in India, manufactured and supplied by Theranica.
  • While the agreement applies only to India, the companies will continue discussions about expanding to additional territories outside the United States and China.
  • "This agreement aligns exactly with the vision of Theranica's founders," said Alon Ironi, CEO and co-founder of Theranica.

Vyant Bio Engages LifeSci Capital to Explore Strategic Alternatives

Retrieved on: 
Wednesday, January 4, 2023
Management, Drug discovery, Disclosure, Neurological disorder, Disease, Board of Management St. Molaga's National School v The Secretary General of the Department of Education and Science, Machine learning, Therapy, Conference, Neurodegeneration, Pharmaceutical industry

CHERRY HILL, N.J., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders.

Key Points: 
  • CHERRY HILL, N.J., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders.
  • The Company’s proprietary central nervous system (“CNS”) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning.
  • Today, Vyant Bio announced that it has engaged LifeSci Capital as its financial advisor to assist in exploring a range of strategic alternatives focused on enhancing shareholder value.
  • In addition, the Company announced that it is participating in BIO’s One-on-One Partnering event in San Francisco taking place at the same time as the annual JP Morgan Healthcare Conference.

Athersys Appoints Joseph Nolan to Its Board of Directors

Retrieved on: 
Thursday, January 5, 2023
Health, Stem Cells, Genetics, Research, Science, Pharmaceutical, Biotechnology, Takeda Pharmaceutical Company, Tulane University, Biotechnology, Therapy, Regenerative medicine, MBA, Marathon Pharmaceuticals, Abbott Laboratories, Patient, Novartis, University, Laboratory, Conference, Neurological disorder, Notre Dame, Management, Pharmaceutical industry, Novartis Gene Therapies

Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today the appointment of Joseph “Joe” Nolan to its Board of Directors, effective January 4, 2023.

Key Points: 
  • Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today the appointment of Joseph “Joe” Nolan to its Board of Directors, effective January 4, 2023.
  • Mr. Nolan is an experienced biotechnology and pharmaceutical executive who currently serves as Chief Executive Officer of Jaguar Gene Therapy, LLC.
  • With this appointment, Athersys has five Directors, four of whom are independent.
  • “I’m proud to join the Athersys Board and am enthusiastic about MultiStem’s potential across a range of unmet medical needs.

Worldwide SARM1 Inhibitors Industry to 2040 - Current and Future Market Opportunities - ResearchAndMarkets.com

Retrieved on: 
Tuesday, December 20, 2022
Biotechnology, Pharmaceutical, Health, UN, Multiple sclerosis, Death, Sterile alpha motif, Neurodegeneration, Research, Alzheimer's disease, Neurological disorder, Amyotrophic lateral sclerosis, Publication, SARM1, ALS, Patient, Vance DeGeneres, Therapy, First Nations in Ontario, United Nations, Parkinson's disease, Fine chemical, Pharmaceutical industry, Distribution (marketing), Creative industries

This report features an extensive study of the current landscape, offering an informed opinion on the likely adoption of SARM1 inhibitors therapeutics in the healthcare domain, till 2040.

Key Points: 
  • This report features an extensive study of the current landscape, offering an informed opinion on the likely adoption of SARM1 inhibitors therapeutics in the healthcare domain, till 2040.
  • Neurological disorders are considered the second leading cause of death and the primary cause of long-term disability, worldwide.
  • What are the recent developments and strategic initiatives undertaken by players engaged in this market space related to research and development of SARM1 inhibitors therapeutics?
  • How is the current and future market opportunity likely to be distributed across key market segments?

FDA Grants Accelerated Approval for Alzheimer's Disease Treatment

Retrieved on: 
Friday, January 6, 2023
Accelerated approval (FDA), Priority review, Amyloid-related imaging abnormalities, Dizziness, Food, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Seizure, Brain, Center for Drug Evaluation and Research, Vomiting, Risk, ARIA, Neurological disorder, Disease, Research, Nausea, Patient, Dose, Bleeding, Safety, Pathology, PET, Neuron, FDA, Antibody, Headache, Blood pressure, Confusion, Fast Track, Trial of the century, Pharmaceutical industry, Medical imaging, Alzheimer's disease

SILVER SPRING, Md., Jan. 6, 2023 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Leqembi (lecanemab-irmb) via the Accelerated Approval pathway for the treatment of Alzheimer's disease.

Key Points: 
  • SILVER SPRING, Md., Jan. 6, 2023 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Leqembi (lecanemab-irmb) via the Accelerated Approval pathway for the treatment of Alzheimer's disease.
  • Leqembi is the second of a new category of medications approved for Alzheimer's disease that target the fundamental pathophysiology of the disease.
  • "This treatment option is the latest therapy to target and affect the underlying disease process of Alzheimer's, instead of only treating the symptoms of the disease."
  • These results support the accelerated approval of Leqembi, which is based on the observed reduction of amyloid beta plaque, a marker of Alzheimer's disease.

BIORCHESTRA to pursue partnership at the 41st Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Friday, January 6, 2023
JPM, RNA interference, Neurological disorder, Research, Nanomedicine, Therapy, Pharmaceutical industry, Medical device

BOSTON, Jan. 6, 2023 /PRNewswire/ -- BIORCHESTRA, South Korea and Boston based RNAi therapeutics biotech company focused on brain diseases with a diverse pipeline and brain-targeting RNAi Nanomedicine Platform (BTRiNTM) will attend the JPM@BIO with the goal of pursuing diverse transactions and research collaborations in San Francisco during the 41st Annual J.P. Morgan Healthcare conference.

Key Points: 
  • BOSTON, Jan. 6, 2023 /PRNewswire/ -- BIORCHESTRA, South Korea and Boston based RNAi therapeutics biotech company focused on brain diseases with a diverse pipeline and brain-targeting RNAi Nanomedicine Platform (BTRiNTM) will attend the JPM@BIO with the goal of pursuing diverse transactions and research collaborations in San Francisco during the 41st Annual J.P. Morgan Healthcare conference.
  • Details of the events are as follows:
    During the J.P. Morgan Healthcare conference week, Dr. Branden RYU, CEO and Founder of BIORCHESTRA, will hold one-on-one meetings with global pharmaceutical companies, introducing BIORCHESTRA's Brain-targeting RNAi Nanomedicine Platform (BTRiNTM) and brain disease therapeutic candidates and exploring collaboration opportunities.
  • "BIORCHESTRA's ultimate goal is to develop therapeutics that shift the paradigm in disease treatment.
  • I expect to have in-depth discussions with key decision makers from global pharma companies, on what we could achieve together, with enabling technology from our novel therapeutics combined with our proprietary RNAi Nanomedicine platform."

Tempero Bio Announces FDA Clearance of Investigational New Drug (IND) Application for TMP-301 for the Treatment of Alcohol and Other Substance Use Disorders

Retrieved on: 
Wednesday, January 4, 2023
Neurological disorder, National Institute on Drug Abuse, NIDA, Patient, Addiction, Food, Bio, Brain, Disease, CUD, FDA, Public health, Clinical trial, Glutamate (neurotransmitter), Multimedia, CNS, IND, Drug, Software, Research, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NIH, NAM, Pharmaceutical industry, Health

Tempero Bio's TMP-301 is being researched to treat alcohol and other substance use disorders through the use of its mGluR5 NAM that modulates glutamate signaling in the brain.

Key Points: 
  • Tempero Bio's TMP-301 is being researched to treat alcohol and other substance use disorders through the use of its mGluR5 NAM that modulates glutamate signaling in the brain.
  • Alcohol and other substance use disorders affect over 40 million people in the US alone and have limited treatment options.
  • Tempero Bio, Inc, a clinical-stage biopharmaceutical company focused on developing transformative therapies for the treatment and prevention of alcohol and other substance use disorders, today announced the U.S. Food and Drug Administration (FDA) clearance of its Investigational New Drug (IND) application for TMP-301.
  • Tempero Bio is committed to bringing innovative medicines forward that change the course of treatment in substance use disorders and related conditions.

Free Webinar - Learning Differences, Brain Trauma, or is it something else?

Retrieved on: 
Tuesday, January 3, 2023
Hand, Trauma, Education, CISD, Tactical Combat Casualty Care, Metabolic pathway, Rehabilitation, Brain, Student, PPCS, Government budget balance, Brain damage, University, Barnstable Academy, Emergency department, Fusion Academy, USAMRMC, Quantitative electroencephalography, TBI, FDA, Traumatic brain injury, Adolescence, Concussion, Physical medicine and rehabilitation, University of Pittsburgh, Virginia Commonwealth University, MPH, Parent, Pittsburgh, FEG, Hack, Science, MS, Head injury, Research, Peak Performance Project, Department of Defense Education Activity, Management, Medical imaging, Medicine, Nature, MD, Neurological disorder, Neurosurgery

GRAND RAPIDS, Mich., Jan. 3, 2023 /PRNewswire/ -- Fusion Education Group will host a free webinar with Neurologics which will help families better understand that traumatic brain injuries are repairable, and the potential recovery paths available to children. A recent study found that 1 in 4 children who suffered a minor head injury are likely to suffer from chronic post-concussion syndrome.

Key Points: 
  • "The science around brain injury is promising," said Fusion Education Group Chief Executive Officer Peter Ruppert.
  • Families are encouraged to register for the webinar to discover if the trauma from a head injury is impacting their student's learning.
  • Odell-Barber and Hack will help parents gain a better understanding of brain trauma and repair through accurate assessment.
  • About Neurologics : Headquartered in Southern California, Neurologics is an innovative and highly effective brain function assessment and optimization company utilizing FDA-registered technology and proprietary software.

CEFALY Technology Launches Trade-In Program for Purchasers of the New CEFALY Connected Migraine Treatment Device

Retrieved on: 
Tuesday, December 20, 2022
Customer service, Neurological disorder, Migraine, FDA, Trigeminal nerve, Electronics, Pharmaceutical industry, Medical device

It syncs with the CeCe Migraine Management app, giving users the ability to track CEFALY sessions and log migraine attacks on their mobile device.

Key Points: 
  • It syncs with the CeCe Migraine Management app, giving users the ability to track CEFALY sessions and log migraine attacks on their mobile device.
  • CEFALY, which was first introduced in 2008, is the only FDA-cleared migraine treatment device used for the treatment and prevention of migraine that is available without a prescription.
  • "The CEFALY Connected delivers the same clinically proven migraine treatment and prevention as earlier devices, while also empowering users with personalized insights into their treatment history and migraine patterns."
  • CEFALY Technology is the maker of CEFALY, an FDA-cleared, over-the-counter wearable medical device clinically proven to help reduce migraine frequency and relieve migraine pain.